TABLE 1:

Patient characteristics, therapy, and outcome

Patient no.	1	2	3	4	5	6	7	8	9	10
Sex/age (y)	M/58	M/58	M/60	F/61	F/61	M/58	M/60	F/60	M/19	M/45
Clinical symptoms	Focal motor/sensory deficits	Hemiparesis	Ataxia, diplopia, neuropsychologic deficits, somnolence	Cerebellar syndrome, neuropsychologic deficits	Focal sensory deficits	Epilepsy (grand-mal)	Epilepsy (grand-mal), ataxia, nmestic deficits, incontinence	None	Epilepsy (grand-mal status)	Neuropsychologic deficits
KPS (initially/at last follow-up), %	40/30	80/90	80/50	80/80	80.60	70/90	60/60	70/100	20/100	20/100
Median time to diagnosis (months)	1	1	1.5	2.5	0.5	32	2	0.5	3.5	6.5
Biopsy site	Cervicothoracic spinal cord	Right parietal	Left basal ganglia	Left parietal	Right thalamus	Left temporal	Right frontal	Left occipital	Right temporal	Left frontal
Histopathology, growth fraction (Ki67/MIB-1)	T-cell (perivascular infiltrates; small, mature lymphocytes); Ki-67/MIB-1: 20%	T-cell (perivascular infiltrates; small, mature lymphocytes); Ki-67/MIB-1: 1%	B-cell, not specified (perivascular infiltrates; small, mature lymphocytes with round nuclei); Ki-67/MIB-1: 1%	B-cell, not specified (perivascular infiltrates; small, mature lymphocytes with round nuclei); Ki-67/MIB-1: 5%	T-cell (perivascular infiltrates; small, mature lymphocytes with irregularly shaped nuclei); Ki-67/MIB-1: <5%	B-cell, lymphoplasmacellular (small, mature lymphocytes with round, eccentric, nuclei); Ki-67/MIB-1: <5%	Follicular lymphoma (diffuse variant), grade 1 (small cells with cleaved nuclei (centrocytes), 3 large cells per hpf with scant, basophillic cytoplasm, round to oval nuclei, 1–2 nucleoli (centroblasts); Ki-67/MIB-1: <5%	B-cell, not specified (infiltrates with small, mature lymphocytes with round nuclei); Ki-67/MIB-1: 15%	B-cell lymphoplasmacellular (small, mature lymphocytes with round, eccentric, nuclei); Ki-67/MIB-1; 2%	B-cell, not specified (perivascular, small, mature lymphocytes with round nuclei); Ki-67/MIB-1: 4%
Therapy	Total resection, HDMTX, local RT	HDMTX, WBI	HDMTX	HDMTX	BMPD, MTX i.th.	none	BMPD, MTX i.th., CHOP, WBI	HDMTX	HDMTX	HDMTX, WBI
PFS/OAS (months)	3/5.5	27+/27+	44.5+/44.5+	22.5/22.5	2/3	14.5+/14.5+	54+/54+	58+/58+	33.5+/33.5+	10+/10+
Last status	Died due to sepsis	CR	CR	Died due to acute renal failure	Died due to lymphoma	CR	CR	CR	NC	CR

Note.—KPS indicates Karnofsky performance score; Ki-67/MIB-1, growth fraction of neoplastic cells as evidenced by staining with Ki-67 or MIB-1 antibody; hpf, high-power field of 0.159 mm²; (HD)MTX, (high-dose) methotrexate; RT, radiotherapy; WBI, whole-brain irradiation; i.th., intrathecally; BMPD, BCNU, methotrexaste, procarbazine, dexamethasone; CHOP, cyclophosphamide, doxorubicin, vincristine, prednisolone; PFS, progression-free survival; OAS, overall survival; CR, complete response; NC, no change.